Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cytomegalovirus Vaccines
Studies from Johann Wolfgang Goethe University, Institute for Virology in the area of cytomegalovirus vaccines described
March 12th, 2008
New research, 'Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies,' is the subject of a report. According to recent research from Mainz, Germany, "Exogenous introduction of particle-associated proteins of human cytomegalovirus (HCMV) into the major histocompatibility complex (MHC) class I presentation pathway by subviral dense bodies (DB) is an effective way to sensitize cells against CD8 T-cell (CTL) recognition and killing. Consequently, these particles have been proposed as a platform for vaccine development." "We have developed a...
Source: Vaccine Weekly (2008-03-12)
|
